We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+31.41%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.98B
AUM Growth
+$856M
Cap. Flow
+$11.5M
Cap. Flow %
0.29%
Top 10 Hldgs %
64.68%
Holding
36
New
2
Increased
14
Reduced
6
Closed
1

Top Buys

1
CRSP icon
CRISPR Therapeutics
CRSP
+$28M
2
NKTR icon
Nektar Therapeutics
NKTR
+$25.3M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$17.9M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$17.2M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$13.3M

Top Sells

1
IONS icon
Ionis Pharmaceuticals
IONS
+$65.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$25.5M
3
INCY icon
Incyte
INCY
+$15.3M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13M
5
GILD icon
Gilead Sciences
GILD
+$12.6M

Sector Composition

1 Healthcare 96.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
1
Ionis Pharmaceuticals
IONS
$8.99B
$627M 15.76%
7,725,000
-1,016,334
-12% -$65.6M
INCY icon
2
Incyte
INCY
$23.4B
$311M 7.83%
3,620,000
-188,322
-5% -$15.3M
NBIX icon
3
Neurocrine Biosciences
NBIX
$17.2B
$297M 7.46%
3,366,786
+23,696
+0.7% +$1.98M
VRTX icon
4
Vertex Pharmaceuticals
VRTX
$123B
$239M 6.01%
1,300,000
-70,445
-5% -$13M
SAGE
5
DELISTED
Sage Therapeutics
SAGE
$219M 5.5%
1,375,229
– –
CELG
6
DELISTED
Celgene Corp
CELG
$208M 5.22%
2,200,000
-103,875
-5% -$9.08M
AGIO icon
7
Agios Pharmaceuticals
AGIO
$2.36B
$201M 5.05%
2,978,134
+100,000
+3% +$5.82M
ALXN
8
DELISTED
Alexion Pharmaceuticals
ALXN
$178M 4.47%
1,314,428
– –
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$35.7B
$152M 3.83%
1,631,089
+59,700
+4% +$4.99M
ESPR
10
DELISTED
Esperion Therapeutics
ESPR
$141M 3.56%
3,522,964
+130,000
+4% +$5.83M
RDUS
11
DELISTED
Radius Health, Inc.
RDUS
$135M 3.4%
6,781,685
+71,409
+1% +$1.3M
HALO icon
12
Halozyme
HALO
$9.23B
$134M 3.37%
8,322,860
– –
ARGX icon
13
argenx
ARGX
$53.8B
$113M 2.84%
904,739
+20,000
+2% +$2.35M
MRNA icon
14
Moderna
MRNA
$24.5B
$97.4M 2.45%
4,785,681
– –
MYOV
15
DELISTED
Myovant Sciences Ltd.
MYOV
$85.9M 2.16%
3,597,882
– –
ICPT
16
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$78M 1.96%
696,976
+121,257
+21% +$13.2M
GILD icon
17
Gilead Sciences
GILD
$167B
$74.3M 1.87%
1,142,204
-190,000
-14% -$12.6M
NKTR icon
18
Nektar Therapeutics
NKTR
$2.31B
$67.9M 1.71%
134,712
+42,647
+46% +$25.3M
EXEL icon
19
Exelixis
EXEL
$14.1B
$67.5M 1.7%
2,835,000
– –
AKCA
20
DELISTED
Akcea Therapeutics Inc
AKCA
$67.4M 1.69%
2,377,638
-8,833
-0.4% -$257K
MYOK
21
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$65.8M 1.65%
1,264,913
+387,647
+44% +$17.9M
MGNX icon
22
MacroGenics
MGNX
$285M
$61.1M 1.54%
3,400,000
+116,728
+4% +$2.02M
WVE icon
23
Wave Life Sciences
WVE
$1.12B
$56.9M 1.43%
1,465,002
– –
VYGR icon
24
Voyager Therapeutics
VYGR
$192M
$54.9M 1.38%
2,865,841
– –
BOLD
25
DELISTED
Audentes Therapeutics, Inc
BOLD
$53.4M 1.34%
1,369,604
+600,200
+78% +$17.2M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q1 2019 Portfolio in Review

As of Q1 2019, BB Biotech held 36 positions worth $3.98B, up 27% from $3.12B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

BB Biotech's Q1 2019 filing shows 2 new, 14 increased, 6 reduced and 1 closed positions. Its largest new stake was CRISPR Therapeutics: 810,462 shares worth $28.9M. The largest sale was Ionis Pharmaceuticals, an estimated $65.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

  • BB Biotech's largest Q1 2019 buy was CRISPR Therapeutics: 810,462 shares worth $28.9M.
  • BB Biotech added most to Nektar Therapeutics in Q1 2019, an estimated $25.3M increase.
  • BB Biotech's biggest Q1 2019 reduction was Ionis Pharmaceuticals, cutting an estimated $65.6M.
  • BB Biotech fully exited Regeneron Pharmaceuticals in Q1 2019, selling an estimated $25.5M.
  • BB Biotech's ten largest holdings make up 65% of its $3.98B portfolio in Q1 2019.
  • BB Biotech opened 2 new positions and closed 1 in Q1 2019.
  • BB Biotech's portfolio value rose 27% quarter-over-quarter to $3.98B.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.